Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aspirin + atenolol + hydrochlorothiazide + ramipril
- Development stage
- Unknown
- Lead developer
- Cadila Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Aspirin + atenolol + hydrochlorothiazide + ramipril** was a blinded oral fixed-dose comparator capsule evaluated in the phase 2 Indian Polycap Study (TIPS) in people with cardiovascular risk factors but without established cardiovascular disease. The regimen contained hydrochlorothiazide 12.5 mg, atenolol 50 mg, ramipril 5 mg, and aspirin 80 mg once daily. It combines a thiazide diuretic, beta-1 adrenergic receptor blocker, angiotensin-converting enzyme inhibitor, and antiplatelet agent to lower blood pressure and heart rate while reducing platelet-mediated thrombosis. This four-drug trial formulation is distinct from Polycap, which additionally contains simvastatin. ([acc.org](https://www.acc.org/Latest-in-Cardiology/Clinical-Trials/2010/02/23/19/25/TIPS--Presented-at-ACC09i2))
- Other names
- hydrochlorothiazide + atenolol + ramipril + aspirinThiazide + Ramipril+Atenolol+Aspirin
02
Targets
ACE (Angiotensin Converting Enzyme)ADRB1 (β1)SLC12A3 (Thiazide-sensitive sodium-chloride cotransporter)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on aspirin + atenolol + hydrochlorothiazide + ramipril.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aspirin + atenolol + hydrochlorothiazide + ramipril.